**
In a troubling development for public health advocacy, internal records reveal that top officials from the Trump administration met with Bayer CEO Bill Anderson to discuss ongoing litigation related to the company’s glyphosate-based herbicides, including Roundup. The meeting, which took place on June 17, 2025, at the Environmental Protection Agency (EPA), came just months before the government took significant steps to bolster Bayer’s position in the Supreme Court regarding claims that its products can cause cancer.
Meeting Details and Implications
The June meeting involved key figures from the EPA, including Lee Zeldin, the agency’s administrator, and Nancy Beck, the principal deputy assistant administrator in the Office of Chemical Safety and Pollution Prevention. The agenda reportedly included discussions about “legal/judicial issues” and the potential for “Supreme Court action” concerning glyphosate. This gathering occurred less than two weeks before the Supreme Court requested input from the Justice Department on whether it should take up Bayer’s case.
Bayer is currently facing thousands of lawsuits from individuals alleging that their cancer diagnoses are linked to exposure to glyphosate herbicides. The company has maintained that it is not liable for any damages if the EPA does not mandate a cancer warning on its products, a stance that has been contested in various courts.
Administration’s Actions Following the Meeting
The nature of the discussions and the subsequent actions by the Trump administration have raised eyebrows among public health advocates. Following the June meeting, the administration has taken multiple steps that appear to favour Bayer. On December 1, 2025, the Trump-appointed solicitor general, D John Sauer, urged the Supreme Court to hear Bayer’s case, which the court agreed to do, scheduling a hearing for April 27, 2026. Furthermore, the White House invoked the Defense Production Act on February 18, 2026, to protect glyphosate production and provide immunity for glyphosate manufacturers.
In a move that further solidified its support for Bayer, Sauer filed an amicus brief on March 2, 2026, officially backing Bayer’s position in the ongoing legal battles. This series of actions has prompted concerns about the prioritisation of corporate interests over public health.
Voices of Concern
Environmental health advocates have expressed alarm over the implications of the meeting and the subsequent governmental actions. Nathan Donley, director of the Center for Biological Diversity, remarked, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” He emphasised that the meeting exemplifies the significant influence corporations can exert on regulatory decisions that directly affect public health.
Whitney Di Bona, a consumer safety attorney, also raised concerns, stating, “It’s alarming that the CEO of a major pesticide company can have private meetings with the EPA to discuss limiting the company’s liability.” She questioned whether the EPA had afforded similar opportunities for dialogue to the numerous individuals claiming harm from glyphosate exposure.
Naomi Oreskes, a Harvard professor who studies corporate influence on regulation, noted that the access granted to industry leaders often contrasts sharply with the limited opportunities available for affected citizens. “This high-level meeting seems part of a pattern where industry gets a seat at the table while the public is left in the dark,” she stated.
Industry’s Response
In response to the revelations about the meeting and subsequent government actions, Bayer described the discussions at the EPA as a “normal part of the regulatory process.” The company insisted it has been forthcoming about its position on glyphosate litigation. Bayer also pointed out that such meetings are not exclusive to corporate representatives, citing interactions with various stakeholder groups, including environmental organisations.
Despite these assertions, advocates remain sceptical, highlighting the long history of chemical companies exerting pressure on regulatory agencies without equivalent accountability to the public.
Why it Matters
The implications of this meeting and the subsequent support for Bayer by the Trump administration extend far beyond corporate interests; they raise critical questions about the integrity of regulatory processes and the prioritisation of public health. As the legal battles over glyphosate continue, the findings underscore the need for transparency and accountability in the interactions between government agencies and powerful corporations. With public health at stake, the balance of influence must be carefully scrutinised to ensure that the voices of those affected by these products are not drowned out by corporate interests.
